Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2

The coronavirus disease outbreak has caused millions of deaths and widespread unemployment globally. Vaccination boosts neutralizing antibody titers and reduce the spread of SARS-CoV-2 virus. Neutralizing antibodies inhibit the interaction of the virus by blocking the binding between the receptor bi...

Full description

Saved in:

Bibliographic Details
Main Author:	Salleh, Faraazlin
Format:	Thesis
Language:	English
Published:	2023
Subjects:	R Medicine RC109-216 Infectious and parasitic diseases
Online Access:	http://eprints.usm.my/60247/1/FARAAZLIN-E.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.60247
record_format	uketd_dc
spelling	my-usm-ep.602472024-04-15T08:28:53Z Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2 2023-08 Salleh, Faraazlin R Medicine RC109-216 Infectious and parasitic diseases The coronavirus disease outbreak has caused millions of deaths and widespread unemployment globally. Vaccination boosts neutralizing antibody titers and reduce the spread of SARS-CoV-2 virus. Neutralizing antibodies inhibit the interaction of the virus by blocking the binding between the receptor binding domain of SARS-CoV-2 and the host receptor surface. The primary aim of this study was to evaluate GenScript cPass and ImmuSAFE COVID+ assays for detecting neutralizing antibody titers using samples collected from second and booster doses of the BNT162b2 vaccine. GenScript cPass and ImmuSAFE COVID+ assays are the current neutralization tests on the market. The evaluation of neutralization tests demonstrated a statistically significant increase in neutralizing antibodies after the booster dose using GenScript cPass. In contrast, ImmuSAFE COVID+ showed a decline in neutralizing antibodies after the booster dose. The demographic data between age and gender against neutralizing antibody titers was also evaluated, showing no correlation between gender and age towards neutralizing antibodies. The study concludes that GenScript cPass and ImmuSAFE COVID+ assays demonstrate the ability in determining neutralizing antibody titers post-vaccination. 2023-08 Thesis http://eprints.usm.my/60247/ http://eprints.usm.my/60247/1/FARAAZLIN-E.pdf application/pdf en public masters Universiti Sains Malaysia Pusat Pengajian Sains Perubatan
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	R Medicine RC109-216 Infectious and parasitic diseases
spellingShingle	R Medicine RC109-216 Infectious and parasitic diseases Salleh, Faraazlin Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
description	The coronavirus disease outbreak has caused millions of deaths and widespread unemployment globally. Vaccination boosts neutralizing antibody titers and reduce the spread of SARS-CoV-2 virus. Neutralizing antibodies inhibit the interaction of the virus by blocking the binding between the receptor binding domain of SARS-CoV-2 and the host receptor surface. The primary aim of this study was to evaluate GenScript cPass and ImmuSAFE COVID+ assays for detecting neutralizing antibody titers using samples collected from second and booster doses of the BNT162b2 vaccine. GenScript cPass and ImmuSAFE COVID+ assays are the current neutralization tests on the market. The evaluation of neutralization tests demonstrated a statistically significant increase in neutralizing antibodies after the booster dose using GenScript cPass. In contrast, ImmuSAFE COVID+ showed a decline in neutralizing antibodies after the booster dose. The demographic data between age and gender against neutralizing antibody titers was also evaluated, showing no correlation between gender and age towards neutralizing antibodies. The study concludes that GenScript cPass and ImmuSAFE COVID+ assays demonstrate the ability in determining neutralizing antibody titers post-vaccination.
format	Thesis
qualification_level	Master's degree
author	Salleh, Faraazlin
author_facet	Salleh, Faraazlin
author_sort	Salleh, Faraazlin
title	Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_short	Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_full	Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_fullStr	Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_full_unstemmed	Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2
title_sort	evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of bnt162b2
granting_institution	Universiti Sains Malaysia
granting_department	Pusat Pengajian Sains Perubatan
publishDate	2023
url	http://eprints.usm.my/60247/1/FARAAZLIN-E.pdf
_version_	1804888897678737408

Evaluation of genscript cpass and immusafe covid+ assays for the detection of neutralizing antibody titers against sars-cov-2 in individuals with second and booster doses of BNT162b2

Similar Items